Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1051 to 1065 of 2580 results for methods

  1. trublood-prostate for triaging and diagnosing people with prostate cancer symptoms (MIB268)

    NICE has developed a medtech innovation briefing (MIB) on trublood-prostate for triaging and diagnosing people with prostate cancer symptoms .

    Medtech innovation briefing
    Published
    13 July 2021

  2. Peptest for diagnosing gastro‑oesophageal reflux (MIB31)

    NICE has developed a medtech innovation briefing (MIB) on Peptest for diagnosing gastro-oesophageal reflux

    Medtech innovation briefing
    Published
    22 May 2015

  3. NICE recommends the use of eculizumab for atypical haemolytic uraemic syndrome (aHUS) only if all the following arrangements are in place: - coordination of eculizumab use through an expert centre - monitoring systems to record the number of people with a diagnosis of atypical - haemolytic uraemic syndrome and the number who have eculizumab, and the dose and duration of treatment - a national protocol for starting and stopping eculizumab for clinical reasons - a research programme with robust methods to evaluate when stopping treatment or dose adjustment might occur.

    stopping eculizumab for clinical reasons - a research programme with robust methods to evaluate when stopping treatment or dose...

    Research recommendation
    Published
    9 June 2015

  4. Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis (TA254)

    Evidence-based recommendations on fingolimod (Gilenya) for highly active relapsing-remitting multiple sclerosis.

    Technology appraisal guidance
    Published
    25 April 2012
    View recommendations

    Sections for TA254

  5. Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy (TA913)

    Evidence-based recommendations on mavacamten (Camzyos) for symptomatic obstructive hypertrophic cardiomyopathy.

    Technology appraisal guidance
    Published
    6 September 2023
    View recommendations

    Sections for TA913

  6. Risankizumab for previously treated moderately to severely active Crohn's disease (TA888)

    Evidence-based recommendations on risankizumab (Skyrizi) for previously treated moderately to severely active Crohn's disease in people 16 years and over.

    Technology appraisal guidance
    Published
    17 May 2023
    View recommendations

    Sections for TA888

  7. Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (TA997)

    Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma in adults.

    Technology appraisal guidance
    Published
    29 August 2024
    View recommendations

    Sections for TA997

  8. Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (TA265)

    Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours.

    Technology appraisal guidance
    Published
    24 October 2012
    View recommendations

    Sections for TA265

  9. Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)

    Evidence-based recommendations on nivolumab (Opdivo) for treating relapsed or refractory classical Hodgkin lymphoma in adults.

    Technology appraisal guidance
    Published
    26 July 2017
    View recommendations

    Sections for TA462

  10. Tirzepatide for treating type 2 diabetes (TA924)

    Evidence-based recommendations on tirzepatide (Mounjaro) for type 2 diabetes in adults.

    Technology appraisal guidance
    Last updated
    1 September 2025
    View recommendations

    Sections for TA924

  11. Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)

    Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.

    Technology appraisal guidance
    Last updated
    1 May 2025
    View recommendations

    Sections for TA878

  12. Digital technologies for applying algorithms to spirometry to support asthma and COPD diagnosis in primary care and community diagnostic centres: early-use assessment

    In development Reference number: GID-HTE10065 Expected publication date:  02 April 2026

    Health technology evaluations
    In development

  13. Topotecan for the treatment of recurrent and stage IVB cervical cancer (TA183)

    Evidence-based recommendations on topotecan for treating recurrent and stage IVB cervical cancer in adults.

    Technology appraisal guidance
    Published
    28 October 2009
    View recommendations

    Sections for TA183

  14. Elbasvir–grazoprevir for treating chronic hepatitis C (TA413)

    Evidence-based recommendations on elbasvir–grazoprevir (Zepatier) for treating genotype 1 or 4 chronic hepatitis C in adults.

    Technology appraisal guidance
    Published
    26 October 2016
    View recommendations

    Sections for TA413

  15. Laparoscopic ventral mesh rectopexy for internal rectal prolapse (HTG475)

    Evidence-based recommendations on laparoscopic ventral mesh rectopexy for internal rectal prolapse in adults. This involves using a piece of sterile material (mesh) to attach the rectum to the lower back bone using keyhole surgery.

    HealthTech guidance
    Published
    20 June 2018
    View recommendations

    Sections for HTG475